Purpose: Approximately 35% of patients with prostate cancer who undergo radical prostatectomy experience prostate specific antigen recurrence within 10 years of surgery. Current prognostic indicators cannot sufficiently detect who is at risk for biochemical recurrence. We evaluated DNA methylation markers for prostate cancer prognosis.
Materials And Methods: We assessed the DNA methylation of 6 marker candidates that were identified in previous studies. Formalin fixed, paraffin embedded tissue sections from a cohort of 605 patients who underwent radical prostatectomy were analyzed using real-time polymerase chain reaction assays. Using a Cox proportional hazard model we determined which markers were significant predictors of biochemical recurrence.
Results: ABHD9, Chr3-EST, GPR7, HIST2H2BF and PITX2 were significantly associated with biochemical recurrence. PITX2 methylation was the strongest predictor of biochemical recurrence, providing additional prognostic information to established clinical factors in patients treated with radical prostatectomy and especially in patients at intermediate risk (Gleason 7). Patients with greater than median PITX2 methylation in the tumors were 4 times more likely to experience biochemical recurrence within 8 years after surgery than patients with less than average methylation.
Conclusions: The prognostic information provided by PITX2 methylation adds significantly to currently used clinical variables such as Gleason grade and stage. Therefore, it could contribute to better counseling in patients with prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2008.11.120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Late erosion of an Adjustable Transobturator Male System (ATOMS) device.
IJU Case Rep
January 2025
Department of Urology Bendigo Health Bendigo Victoria Australia.
Introduction: This report describes late erosion of an Adjustable Transobturator Male System device which was inserted for post-prostatectomy incontinence. The Adjustable Transobturator Male System device eroded the bulbar urethra 5 years post insertion, despite initial improvement of symptoms.
Case Presentation: Following an open radical retropubic prostatectomy, a 64 year-old male patient developed post-prostatectomy incontinence.
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer.
Cancer
January 2025
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: Adverse pathology (AP) is often used as an intermediate end point for long-term outcomes in men with prostate cancer (PCa) who are active surveillance candidates. The association between a commonly used AP definition and long-term outcomes was tested, which identified definitions more strongly linked to a high risk of metastasis.
Methods: Data were reviewed from the Shared Equal Access Regional Cancer Hospital cohort of men undergoing radical prostatectomy (RP) from 1988 to 2020 at nine Veterans Affairs hospitals.
Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel.
Clin Transl Oncol
January 2025
Urology Department, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain.
Introduction: Diagnosing and managing biochemical recurrence (BCR) of prostate cancer (PCa) following primary radical treatment remain a challenge. Implementing next-generation imaging (NGI) techniques has improved metastases detection. However, access to these techniques is heterogeneous, and controversies surround their use and subsequent treatment decisions.
View Article and Find Full Text PDFSingle-fraction high-dose-rate brachytherapy as monotherapy for localized prostate cancer: long-term follow-up study based on meta-analysis.
J Cancer
January 2025
Department of Radiation Oncology, Nanyang Central Hospital, Nanyang, Henan, 473005, China.
Although single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer has been attempted in clinical trials, there is currently a lack of relevant medical evidence. It is essential to conduct a systematic analysis of the long-term safety and efficacy of SFHDR-BT. Comprehensive and systematic searches for eligible studies were performed in PubMed, Embase, and the Cochrane Library databases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!